[VM-26 salvage therapy for refractory or recurrent germinal testicular cancers].
Four patients with refractory or recurrent germinal testicular cancers were treated with the combination of VM-26 and cis-platinum, and two of them also in combination with radiation therapy. Two complete responses and two partial responses were observed. One partial response was rendered no evidence of disease by sequential radiation therapy. Three of the patients remained to have no evidence of disease from 16, 21 and 22 months. Toxicity was tolerable. VM-26 is an active drug in germinal testicular cancers and plays an important role in salvage therapy, for refractory or recurrent cases.
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D004407:Dysgerminoma / Q000188:drug therapy*; D006801:Humans; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D011034:Podophyllotoxin / Q000031:analogs & derivatives*; D013713:Teniposide / Q000008:administration & dosage*; D013724:Teratoma / Q000188:drug therapy*; D013736:Testicular Neoplasms / Q000188:drug therapy*
D013713:Teniposide; D011034:Podophyllotoxin; D002945:Cisplatin